OJU  Vol.2 No.3 A , October 2012
Changes in Electrocardiogram Findings during Treatment with Gonadotropin-Releasing Hormone Agonist and Surgical Castration for Prostate Carcinoma
Abstract: Purpose: To investigate electrocardiogram (ECG) changes after complete androgen blockade (CAB) achieved by either surgical or medical castration and compare the outcomes of the groups. Methods: Sixty-three consecutive men (between 58 - 86 years of age) requiring CAB for prostate cancer were enrolled in the study. Patients with diabetes mellitus, an additional malignancy, coronary heart disease, atrial fibrillation, heart failure or a medical history of cardiac event in the last 12 months were excluded from the study. Additionally, those who were taking medicine affecting heart rate were excluded. The participants were divided into two groups according to their modality of castration. The first group consisted of 35 patients who received bilateral orchiectomy plus anti-androgen medication. The second group contained 28 patients who accepted gonadotropin-releasing hormone (GnRH) plus anti-androgen therapy. After complete examinations and biochemical tests, the ECG leads of the patients were obtained conveniently. This was then repeated at three- and six-month visits. ECG findings (including heart rate, PR, QRS, QT, corrected QT (QTc) intervals and QT dispersion (QTd)) were recorded and analysed statistically. The groups were then compared in terms of pre- and post-treatment ECG outcomes. Results: Both groups revealed similarly lower heart rate and prolonged PR, QRS, QT, corrected QTc and QTd by the end of six months. By the end of three months, all variables had changed significantly in the orchiectomy group, whereas in the GnRH group, they had not. Conclusion: CAB may result in lower heart rate and prolonged QT, a condition associated with fatal cardiac arrhythmia and sudden death. Therefore, patients receiving CAB should be monitored closely for cardiac adverse effects.
Cite this paper: H. Sağlam, A. Çakar, O. Köse, Ş. Kumsar, S. Budak, S. Gökhan Beyaz and Ö. Adsan, "Changes in Electrocardiogram Findings during Treatment with Gonadotropin-Releasing Hormone Agonist and Surgical Castration for Prostate Carcinoma," Open Journal of Urology, Vol. 2 No. 3, 2012, pp. 153-156. doi: 10.4236/oju.2012.223029.

[1]   A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu and M. J. Thun, “Cancer Statistics,” CA Cancer Journal of Clinicians, Vol. 57, No. 1, 2007, pp. 43-66. doi:10.3322/canjclin.57.1.43

[2]   A. Jemal, F. Bray, M. Center, J. Ferlay, E. Ward and D. Forman, “Global Cancer Statistics,” CA Cancer Journal of Clinicians, Vol. 61, No. 2, 2011, pp. 69-90. doi:10.3322/caac.20107

[3]   A. Karl and B. Konety, “Androgen Deprivation Therapy for Prostate Cancer: Indications, Contraindications and Possible Consequences,” F1000 Medicine Reports, 2009.

[4]   G. W. Chodak, T. Keane and L. Klotz, “Critical Evaluation of Hormonal Therapy for Carcinoma of the Prostate,” Urology, Vol. 60, No. 2, 2002, pp. 201-208. doi:10.1016/S0090-4295(02)01677-1

[5]   V. B. Shahinian, Y. F. Kuo, J. L. Freeman and J. S. Goodwin, “Risk of Fracture after Androgen Deprivation for Prostate Cancer,” The New England Journal of Medicine, Vol. 352, No. 2, 2005, pp. 154-164. doi:10.1056/NEJMoa041943

[6]   F. A. S. Chutz and W. K. Oh, “Neoadjuvant and Adjuvant Therapies in Prostate Cancer,” Urologic Clinics of North America, Vol. 37, No. 1, 2010, pp. 97-104. doi:10.1016/j.ucl.2009.11.012

[7]   C. S. Saigal, J. L. Gore, T. L. Krupski, J. Hanley, M. Schonlau and M. S. Litwin, “Androgen Deprivation Therapy Increases Cardiovascular Morbidity in Men with Prostate Cancer,” Cancer, Vol. 110, No. 7, 2007, pp. 1493-1500. doi:10.1002/cncr.22933

[8]   P.-C. Yang, J. Kurokawa, T. Furukawa and C. E. Clancy, “Acute Effects of Sex Steroid Hormones on Susceptibility to Cardiac Arrhythmias: A Simulation Study,” PLOS Computational Biology, Vol. 6, No. 1, 2010, Article ID: e1000658.

[9]   M. F. Kalin and B. Zumoff, “Sex Hormones and Coronary Disease: A Review of the Clinical Studies,” Steroids, Vol. 55, No. 8, 1990, pp. 30-52. doi:10.1016/0039-128X(90)90058-J

[10]   W. Weidemann and H. Hanke, “Cardiovascular Effects of Androgens,” Cardiovascular Drug Reviews, Vol. 20, No. 3, 2002, pp. 175-198. doi:10.1111/j.1527-3466.2002.tb00086.x

[11]   R. W. Rockhold, “Cardiovascular Toxicity of Anabolic Steroids,” Annual Review of Pharmacology and Toxicology, Vol. 33, 1993, pp. 497-520. doi:10.1146/

[12]   P. Alexandersen, J. Haarbo, I. Byrjalsen, H. Lawaetz and C. Christiansen, “Natural Androgens Inhibit Male Atherosclerosis: A Study in Castrated, Cholesterol-Fed Rabbits,” Circulation Research, Vol. 87, No. 7, 1999, pp. 813-819. doi:10.1161/01.RES.84.7.813

[13]   M. T. Dogru, M. M. Basar, E. Yuvanc, V. Simsek and O. Sahin, “The Relationship between Serum Sex Steroid Levels and Heart Rate Variability Parameters in Males and the Effect of Age,” Turk Kardiyol Dern Ars, Vol. 38, No. 7, 2010, pp. 459-465.

[14]   T. M. Saleh, A. E. Cribb and B. J. Connell, “Role of Estrogen in Central Nuclei Mediating Stroke-Induced Changes in Autonomic Tone,” Journal of Stroke and Cerebrovascular Diseases, Vol. 12, No. 9, 2003, pp. 182- 195. doi:10.1016/S1052-3057(03)00080-6

[15]   S. Tsang, S. Wu, J. Liu and T. M. Wong, “Testosterone Protects Rat Hearts against Ischaemic Insults by Enhancing the Effects of Alpha(1)-adrenoceptor Stimulation,” British Journal of Pharmacology, Vol. 153, No. 4, 2008, pp. 693-709. doi:10.1038/sj.bjp.0707624

[16]   P. Y. Liu, A. K. Death and D. J. Handelsman, “Androgens and Cardiovascular Disease,” Endocrine Reviews, Vol. 24, No. 3, 2003, pp. 313-340. doi:10.1210/er.2003-0005

[17]   N. L. Keating, A. J. O’Malley and M. R. Smith, “Diabetes and Cardiovascular Disease during Androgen Deprivation Therapy for Prostate Cancer,” Journal of Clinical Oncology, Vol. 24, No. 27, 2006, pp. 4448-4456. doi:10.1200/JCO.2006.06.2497

[18]   K. Ezaki, M. Nakagawa, Y. Taniguchi, Y. Nagano, Y. Teshima, K. Yufu, et al., “Gender Differences in the ST Segment: Effect of Androgen-Deprivation Therapy and Possible Role of Testosterone,” Circulation Journal, Vol. 74, No. 11, 2010, pp. 2448-2454. doi:10.1253/circj.CJ-10-0221

[19]   S. M. Al-Khatib, N. M. LaPointe, J. M. Kramer and R. M. Califf, “What Clinicians Should Know About the QT Interval,” The Journal of the American Medical Association, Vol. 289, No. 16, 2003, pp. 2120-2127. doi:10.1001/jama.289.16.2120

[20]   M. Zitzmann and E. Nieschlag, “Androgen Receptor Gene CAG Repeat Length and Body Mass Index Modulate the Safety of Long-Term Intramuscular Testosterone Undecanoate Therapy in Hypogonadal Men,” The Journal of Clinical Endocrinology & Metabolism, Vol. 92, No. 10, 2007, pp. 3844-3853. doi:10.1210/jc.2007-0620

[21]   S. N. Culos-Reed, J. L. Robinson, H. Lau, K. O’Connor and M. R. Keats, “Benefits of a Physical Activity Intervention for Men with Prostate Cancer,” Journal of Sport & Exercise Psychology, Vol. 25, No. 1, 2007, pp. 118-127.

[22]   C. van Noord, M. Dorr , M. C. Sturkenboom, S. M. Straus, T. Reffelmann, S. B. Felix, et al., “The Association of Serum Testosterone Levels and Ventricular Repolarization,” European Journal of Epidemiology, Vol. 25, No. 1, 2010, pp. 21-28. doi:10.1007/s10654-009-9406-z

[23]   G. F. Pecori, P. M. Toja, B. Filippini, J. Michailidis, M. Scacchi, M. S. Badiale, et al., “Increased Prevalence of Prolonged QT Interval in Males with Primary or Secondary Hypogonadism: A Pilot Study,” International Journal of Andrology, Vol. 33, No. 1, 2010, pp. e132-e138. doi:10.1111/j.1365-2605.2009.00985.x

[24]   A. Kirilmaz, E. Bolu, F. Kilicaslan, K. Erinc, M. Uzun, E. Isik, et al., “Comparison of Electrocardiographic Repolarization Patterns between Hypogonad Males and Normal Subjects,” Annals of Noninvasive Electrocardiology, Vol. 8, No. 4, 2003, pp. 284-288. doi:10.1046/j.1542-474X.2003.08404.x